ERBB2 and breast cancer: The interaction between integrins αv, β1, and HER-2 has relevant clinical implications, since overexpression of integrin β1 has been identified as an independent marker of poor prognosis in patients with HER-2-positive breast cancer treated with trastuzumab [37,38].